Helderman, J. Harold.; Kang, Ning; Legorreta, Antonio P.; … - In: Applied Health Economics and Health Policy 8 (2010) 1, pp. 61-68
Background: Generic ciclosporin A modified (CsA) does not have an equivalent pharmacokinetic profile to branded CsA in some transplant populations, potentially leading to negative clinical consequences and increased long-term costs. Objective: To assess direct healthcare costs for de novo renal...